Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial

Start Date10 Jan 2008

Sponsor / Collaborator

Astion Pharma A/S

NCT00565279

/ CompletedPhase 3

Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial.

A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect. ASF1057 is a new drug that acts through a modulation of neurogenic inflammation through important complementary mechanisms of action. This study will test the efficacy and safety of ASF1057 in the treatment of patients with seborrhoeic dermatitis.

Start Date01 Dec 2007

Sponsor / Collaborator

Astion Pharma A/S

EUCTR2007-004627-38-DE

/ Not yet recruitingNot Applicable

Efficacy and safety of ASF 1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, double-blind, vehicle- and placebo controlled, parallel groups, multi-centre trial.

Start Date21 Nov 2007

Sponsor / Collaborator

Astion Pharma A/S

100 Clinical Results associated with Monooctanoin(Astion Pharma A/S)

100 Translational Medicine associated with Monooctanoin(Astion Pharma A/S)

100 Patents (Medical) associated with Monooctanoin(Astion Pharma A/S)

126

Literatures (Medical) associated with Monooctanoin(Astion Pharma A/S)

01 Feb 2025·Food Chemistry

Interface-based kinetic model considering the integral stereoselectivity of lipases on tricapryloylglycerol in a reverse micelle system

Article

Author: Park, Jaehyeon ; Choi, Yoonseok ; Chang, Pahn-Shick

Lipases are essential enzymes with unique selectivity, making them valuable in industrial applications. Understanding the integral stereoselectivity of lipases during triacylglycerol (TAG) hydrolysis is crucial for producing high-value products, such as structured lipids. This study developed an analytical method and an interface-based kinetic model to determine integral stereoselectivities on tricapryloylglycerol (TCG), a medium-chain TAG. The analytical method used an HPLC system that simultaneously separated TCG and its hydrolysates with resolution factors of >2.4 and relative standard deviation of retention times <0.3 % within 15 min. The interface-based kinetic model was established to determine the integral stereoselectivities according to the characteristics of the reaction system. The model provided better fitting results for TCG and trioleoylglycerol hydrolysis than a previous model, indicating the successful application in both medium- and long-chain TAGs. This study expanded our understanding of integral stereoselectivity and could facilitate the development of various structured lipid syntheses.

01 Dec 2024·Journal of Environmental Chemical Engineering

Esterification of caprylic acid with glycerol for medium chain glycerides production catalyzed by waste coconut shell derived sulfonated carbon catalysts

Author: Yu, Guoqiang ; Fu, Guoying ; Zhang, Yingqi ; Wang, Yan ; He, Peihang ; Wu, Guoqiang ; Wu, Guoqaing

Novel and sustainable biomass derived sulfonated carbon solid acid materials (SHTC-WCS-x, x refers to mL sulfuric acid g^-1 carbon) were synthesized by hydrothermal and sulfuric acid treatment of waste coconut shell, which was applied as heterogeneous catalyst for the esterification of caprylic acid with glycerol to produce medium chain glycerides (MCG).It is found that most of the aliphatic carbon structure of carbon materials was transformed into aromatic carbon structure after sulfonation modification.And the sulfonic groups (-SO₃H) are well dispersed on the surface of SHTC-WCS-x through the connection of the C-S bond with carbon materials, which significantly improves the acidity and hydrophilicity of sulfonated carbon catalysts.Furthermore, the activity test results show that the SHTC-WCS-10 catalyst exhibits higher caprylic acid conversion of 77.61% and high MCG selectivity of 99.5%, as well as decent stability in the esterification reaction under solvent-free condition.Esterification mechanisms studies indicate that strong acid sites and surface wettability induced by introducing -SO₃H species play a crucial role in enhancing the production of MCG.

01 Nov 2024·Bioresource Technology

Candida antartica lipase-catalyzed esterification for efficient partial acylglycerol synthesis in solvent-free system: Substrate selectivity, molecular modelling and optimization

Article

Author: Lee, Yee-Ying ; Zhang, Zhen ; Wang, Yong ; Zou, Shuo ; Chen, Jiena

Partial acylglycerols are valued for their emulsifying and stabilizing properties, yet precise green synthesis remains challenging due to low yield and selectivity. This study aimed to elucidate the "lipase selectivity-substrate structure-product composition" relationship to enhance the yield of targeted partial acylglycerol. The results showed that lipase exhibited a greater selectivity towards fatty acids with shorter chain lengths and higher unsaturation. Hydroxyl donors also affected the esterification process, with the enzyme-acyl complex exhibiting selectivity towards hydroxyl donors as follows: glycerol > monoacylglycerol > diacylglycerol. Substrate ratio significantly influenced enzymatic reactions; a 10:1 ratio favored triacylglycerol formation (>80 %), while a 1:1 ratio produced > 90 % partial acylglycerols. Molecular docking simulations revealed that substrates primarily interacted with lipase through hydrogen bonding and hydrophobic interactions. A comprehensive understanding of lipase selectivity patterns could facilitate the design of more efficient reaction systems, enabling the conversion of basic lipid resources into desired high value-added products.

News (Medical) associated with Monooctanoin(Astion Pharma A/S)

13 Jun 2007

·www.biospace.com

Astion Pharma Gets DKK 50 Million to Accelerate Phase III of its Drug Candidate ASF-1096

COPENHAGEN, June 13 /PRNewswire/ -- Astion Pharma A/S has received DKK 50 million of fresh capital from its existing shareholders to accelerate Phase III of its dermatological drug candidate ASF-1096. Astion Pharma recently completed a Phase I development programme for ASF-1096 for the treatment of the serious skin disease, cutaneous lupus erythematosus. The results from the Phase I programme are very favourable, and the Phase II studies with patients are already so far advanced that the company expects to begin Phase III development in the next six to twelve months. That is about six months earlier than expected until now. The consortium of owners has decided to provide additional capital to the company so that the planning of Phase III can be started up immediately. - ASF-1096 is the development programme we expect to move into Phase III first. The capital injection ensures the company time to work with ASF-1096, and it also means that we do not have to lower the pace of development of our other drug candidates, said Henrik Moltke, CFO. One of the other development programmes which the company expects to move into Phase III around the turn of the year is ASF-1057 for the treatment of seborrheic dermatitis. ASF-1057 is currently undergoing Phase II studies in patients in France and the United Kingdom. Astion Pharma A/S develops pharmaceutical products for the treatment of skin diseases. It is estimated that one person in four worldwide will suffer from a skin diseases sometime in life, causing a deterioration of their quality of life. It is the Company's goal to become a leading player in the treatment of skin diseases for which there is currently a major need for new and better therapies. Astion Pharma has a strong platform of proprietary technologies for the development of new and innovative products. The Company pursues development activities through a strong international network of scientific partners and leading contract research organisations. The Company currently has three development projects in Phase II clinical studies in hand dermatitis, seborrheic dermatitis and cutaneous lupus in addition to a large portfolio of product candidates and research projects in earlier phases. For additional information please visit our web site: . Astion Pharma A/S CONTACT: Contact person: Henrik Moltke, CFO, Tel: +45-2244-5404, E-mail:hkm@astion.com

100 Deals associated with Monooctanoin(Astion Pharma A/S)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Seborrheic	Phase 3	Finland	Astion Pharma A/S	28 Nov 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis